CA3148033A1 - Heterotandem bicyclic peptide complex - Google Patents

Heterotandem bicyclic peptide complex Download PDF

Info

Publication number
CA3148033A1
CA3148033A1 CA3148033A CA3148033A CA3148033A1 CA 3148033 A1 CA3148033 A1 CA 3148033A1 CA 3148033 A CA3148033 A CA 3148033A CA 3148033 A CA3148033 A CA 3148033A CA 3148033 A1 CA3148033 A1 CA 3148033A1
Authority
CA
Canada
Prior art keywords
peptide
complex
heterotandem
bicyclic peptide
peptide complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3148033A
Other languages
English (en)
French (fr)
Inventor
Kevin Mcdonnell
Punit UPADHYAYA
Johanna Lahdenranta
Gemma Mudd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of CA3148033A1 publication Critical patent/CA3148033A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3148033A 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex Pending CA3148033A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962880191P 2019-07-30 2019-07-30
US62/880,191 2019-07-30
US201962910088P 2019-10-03 2019-10-03
US62/910,088 2019-10-03
US201962931442P 2019-11-06 2019-11-06
US62/931,442 2019-11-06
US202063022667P 2020-05-11 2020-05-11
US63/022,667 2020-05-11
US202063024715P 2020-05-14 2020-05-14
US63/024,715 2020-05-14
PCT/GB2020/051827 WO2021019243A1 (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex

Publications (1)

Publication Number Publication Date
CA3148033A1 true CA3148033A1 (en) 2021-02-04

Family

ID=71948620

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3148033A Pending CA3148033A1 (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex
CA3147570A Pending CA3147570A1 (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complexes
CA3148039A Pending CA3148039A1 (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3147570A Pending CA3147570A1 (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complexes
CA3148039A Pending CA3148039A1 (en) 2019-07-30 2020-07-30 Heterotandem bicyclic peptide complex

Country Status (15)

Country Link
US (7) US11306123B2 (OSRAM)
EP (4) EP4003528A1 (OSRAM)
JP (5) JP7704732B2 (OSRAM)
KR (3) KR20220051345A (OSRAM)
CN (4) CN114555626B (OSRAM)
AU (3) AU2020322193B2 (OSRAM)
BR (3) BR112022001532A2 (OSRAM)
CA (3) CA3148033A1 (OSRAM)
IL (3) IL290093A (OSRAM)
MX (3) MX2022001288A (OSRAM)
MY (2) MY208497A (OSRAM)
PH (2) PH12022550173A1 (OSRAM)
SA (2) SA522431587B1 (OSRAM)
TW (2) TWI860386B (OSRAM)
WO (4) WO2021019244A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102754019B1 (ko) 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
ES2926195T3 (es) 2017-08-04 2022-10-24 Bicycletx Ltd Ligandos peptídicos bicíclicos específicos de CD137
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
AU2019224659A1 (en) 2018-02-23 2020-10-15 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019193328A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
AU2020269506A1 (en) 2019-05-09 2022-01-06 Bicycletx Limited Bicyclic peptide ligands specific for OX40
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN119192401A (zh) * 2019-10-03 2024-12-27 拜斯科技术开发有限公司 异串联双环肽复合物
CA3189761A1 (en) 2020-08-03 2022-02-10 Gemma Mudd Peptide-based linkers
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
US20250186539A2 (en) * 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2023020485A1 (zh) * 2021-08-17 2023-02-23 南京明德新药研发有限公司 具有新颖结构的多肽药物偶联物及其应用
AU2022356942B2 (en) * 2021-09-29 2025-07-03 Conjustar (Zhuhai) Biologics Co., Ltd. Tricyclic polypeptide conjugated drug and use thereof
WO2023089308A1 (en) * 2021-11-16 2023-05-25 Bicycletx Limited Methods for treating cancer
CN116768978A (zh) * 2022-03-11 2023-09-19 上海智肽生物科技有限公司 Nectin-4靶向肽化合物及其药物偶联物
CN121419788A (zh) * 2023-05-04 2026-01-27 坦博公司 用于体内递送有效载荷的基于四嗪的靶向剂
WO2025191096A1 (en) * 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide
WO2025248261A1 (en) 2024-05-31 2025-12-04 Bicycletx Limited Method for identifying patients

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642514A (en) 1946-08-10 1953-06-16 American Cyanamid Co Ion exchange process with magnetic ion exchange resins
GB1239978A (en) 1968-07-15 1971-07-21 Permutt Company Ltd Ion-exchange processes
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
WO1998019705A1 (en) 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
US6410275B1 (en) 1997-05-02 2002-06-25 Biomerieux, Inc. Disposable test devices for performing nucleic acid amplification reactions
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
EP1115888B1 (en) 1998-09-24 2008-03-12 Indiana University Research and Technology Corporation Water-soluble luminescent quantum dots and bioconjugates thereof
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
EA006227B1 (ru) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7071189B2 (en) 2001-04-27 2006-07-04 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1487972T3 (en) 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
EP1569956B1 (en) 2002-12-12 2014-02-26 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
US7425553B2 (en) 2003-05-30 2008-09-16 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
CA2531069A1 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
CA2505655C (en) 2004-04-28 2013-07-09 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP4801096B2 (ja) 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
PL1866328T3 (pl) 2005-03-22 2011-05-31 Rohto Pharma Peptydy zwiększające wytwarzanie kolagenu lub kwasu hialuronowego
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
EP2757099B1 (en) 2005-05-12 2017-08-23 AbbVie Bahamas Limited Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
AU2006302179C1 (en) 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
RU2439074C2 (ru) 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
CA2663454C (en) 2006-09-15 2015-04-21 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
CN101232326B (zh) 2007-01-22 2012-01-11 中兴通讯股份有限公司 用于无源光网络系统的动态带宽分配装置及其实现方法
US8486941B2 (en) 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100056438A (ko) 2007-06-18 2010-05-27 메디뮨 엘엘씨 ＥｐｈＡ2 및 ＥｒｂＢ2를 발현하는 세포의 상승적 치료 방법
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
WO2009097397A2 (en) 2008-01-30 2009-08-06 Dyax Corp. Metalloproteinase binding proteins
CN101497878B (zh) 2008-01-30 2012-11-07 房学迅 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用
WO2009098450A2 (en) 2008-02-05 2009-08-13 Medical Research Council Methods and compositions
DK2257309T3 (da) 2008-02-27 2020-01-20 Yeda Res And Development Company Ltd Rgd-(bakterie)chlorophyl-konjugater til anvendelse ved diagnose af tumorer, der omfatter nekrotiske domæner
TWI444382B (zh) 2008-03-11 2014-07-11 Incyte Corp 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
FR2932189A1 (fr) 2008-06-10 2009-12-11 Commissariat Energie Atomique Biopuces pour la detection de l'activite enzymatique d'une enzyme protease
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8834926B2 (en) 2008-08-08 2014-09-16 University Of Delaware Macromolecular diffusion and release from self-assembled β-hairpin peptide hydrogels
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
AU2010249719A1 (en) 2009-05-19 2012-05-31 Aic Blab Company Composite current collector and methods therefor
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
EA021897B1 (ru) 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Циклические пептиды, специфичные к рецептору меланокортина-1
EP2949670B1 (en) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2011079015A1 (en) 2009-12-21 2011-06-30 The Regents Of The University Of California Rgd-containing cyclic peptides
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
JP2013518807A (ja) 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
SMT201900074T1 (it) 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130072598A1 (en) 2011-03-18 2013-03-21 Board Of Regents Of The University Of Nebraska Thermoplastics from Distillers Dried Grains and Feathers
NO2694640T3 (OSRAM) 2011-04-15 2018-03-17
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
RU2745572C2 (ru) 2011-10-07 2021-03-29 БайсиклРД Лимитед Модуляция специфичности структурированных белков
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
BR112015006368B1 (pt) 2012-09-24 2022-02-08 Medimmune Limited Processo para produção de linha celular eucariótica estável
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
US9790286B2 (en) * 2013-01-02 2017-10-17 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis
US10450354B2 (en) 2013-03-12 2019-10-22 Molecular Templates, Inc. CD20-binding immunotoxins for inducing cellular internalization and methods using same
US20140274759A1 (en) 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
WO2014142237A1 (ja) 2013-03-15 2014-09-18 日本ゼオン株式会社 中空重合体粒子の水性分散液およびその製造方法
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
EP2999483B1 (en) 2013-05-23 2018-10-31 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
WO2015013330A2 (en) 2013-07-22 2015-01-29 Kineta One, Llc Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
KR102488220B1 (ko) 2013-09-25 2023-01-12 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
US10294274B2 (en) 2013-10-28 2019-05-21 Bicyclerd Limited Polypeptide ligands specific for plasma kallikrein
EP3527569B1 (en) 2014-02-03 2021-08-25 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye
CN106415269B (zh) 2014-05-08 2020-11-27 贵州美鑫达医疗科技有限公司 直接免疫组织化学测定
HUE045872T2 (hu) 2014-05-21 2020-01-28 Entrada Therapeutics Inc Sejteket penetráló peptidek és ezek elõállítására és alkalmazására szolgáló eljárások
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CN115093463A (zh) 2014-09-30 2022-09-23 波利弗尔股份公司 β-发夹肽模拟物
AU2015335725B2 (en) 2014-10-24 2021-06-03 Research Corporation Technologies, Inc. Small antibody-like polypeptides that bind to EphA2 receptor
KR102754019B1 (ko) 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
US10335495B2 (en) 2014-12-04 2019-07-02 Celgene Corporation Biomolecule conjugates
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
CN107529836A (zh) 2015-04-22 2018-01-02 三井化学株式会社 具有关节用支撑体部的衣物、及膝用支撑体
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
CN107810190A (zh) 2015-04-28 2018-03-16 洛桑联邦政府综合工科学校（Epfl) 酶活化因子XII (FXIIa)的新型抑制剂
EA201792441A2 (ru) 2015-05-06 2018-06-29 Янссен Байотек, Инк. Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
RU2754466C2 (ru) * 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
US9963495B2 (en) 2015-10-27 2018-05-08 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
WO2017160879A1 (en) 2016-03-15 2017-09-21 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
JP2019512477A (ja) 2016-03-16 2019-05-16 メリマック ファーマシューティカルズ インコーポレーティッド エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
MX2018012803A (es) * 2016-04-20 2019-06-24 Hangzhou Dac Biotech Co Ltd Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular.
WO2017182672A1 (en) * 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
KR20190014525A (ko) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
US10441663B2 (en) 2016-11-27 2019-10-15 Bicyclerd Limited Methods for treating cancer
US11730819B2 (en) 2016-12-23 2023-08-22 Bicycletx Limited Peptide derivatives having novel linkage structures
CA3046156A1 (en) 2016-12-23 2018-06-28 Bicycletx Limited Peptide ligands for binding to mt1-mmp
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2018222987A1 (en) 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
ES2926195T3 (es) 2017-08-04 2022-10-24 Bicycletx Ltd Ligandos peptídicos bicíclicos específicos de CD137
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
EP3668550A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
IL313068A (en) 2017-11-07 2024-07-01 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
WO2019136442A1 (en) 2018-01-08 2019-07-11 Kleo Pharmaceuticals, Inc. Cd16a binding agents and uses thereof
AU2019224659A1 (en) 2018-02-23 2020-10-15 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019193328A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
WO2019226617A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810325D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
SG11202104356VA (en) 2018-10-30 2021-05-28 Bicyclerd Ltd Bt1718 for use in treating cancer
SG11202106081YA (en) 2018-12-13 2021-07-29 Bicycletx Ltd Bicyclic peptide ligands specific for mt1-mmp
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
US10882987B2 (en) 2019-01-09 2021-01-05 Nova Chemicals (International) S.A. Ethylene interpolymer products having intermediate branching
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
JP2022528887A (ja) 2019-04-02 2022-06-16 バイスクルテクス・リミテッド バイシクルトキシンコンジュゲートおよびその使用
AU2020269506A1 (en) 2019-05-09 2022-01-06 Bicycletx Limited Bicyclic peptide ligands specific for OX40
TWI869398B (zh) 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4013501A1 (en) 2019-08-13 2022-06-22 BicycleTX Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
CN119192401A (zh) * 2019-10-03 2024-12-27 拜斯科技术开发有限公司 异串联双环肽复合物
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
WO2021074647A1 (en) 2019-10-16 2021-04-22 Bicyclerd Limited Methods for treating cancer
US20230025916A1 (en) 2019-11-27 2023-01-26 Bicycle TX Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
IT202000001231A1 (it) 2020-01-22 2021-07-22 Celery S R L Nuovi ceppi di batteri lattici, composizione alimentare che li comprende, preparazione di tale composizione
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
CN115697417A (zh) 2020-05-20 2023-02-03 拜斯科技术开发有限公司 Nectin-4特异性的双环肽配体及其用途
US20230233698A1 (en) 2020-06-12 2023-07-27 Bicycletx Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
CA3189761A1 (en) 2020-08-03 2022-02-10 Gemma Mudd Peptide-based linkers
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
WO2022148969A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2022148974A2 (en) 2021-01-08 2022-07-14 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
US20240197897A1 (en) 2021-01-08 2024-06-20 Bicycle TX Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
CA3229976A1 (en) 2021-09-03 2023-03-09 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
WO2023089308A1 (en) 2021-11-16 2023-05-25 Bicycletx Limited Methods for treating cancer

Also Published As

Publication number Publication date
IL290090A (en) 2022-03-01
US20210040154A1 (en) 2021-02-11
US20210069287A1 (en) 2021-03-11
US20240336656A1 (en) 2024-10-10
MY208496A (en) 2025-05-13
MY208497A (en) 2025-05-13
SA522431587B1 (ar) 2024-04-24
BR112022001521A2 (pt) 2022-07-12
TWI860386B (zh) 2024-11-01
AU2020322193A1 (en) 2022-03-17
CN114521197A (zh) 2022-05-20
PH12022550171A1 (en) 2023-05-15
EP4003528A1 (en) 2022-06-01
US11312749B2 (en) 2022-04-26
JP2022542286A (ja) 2022-09-30
KR20220054309A (ko) 2022-05-02
TWI862640B (zh) 2024-11-21
US11306123B2 (en) 2022-04-19
US20230129258A1 (en) 2023-04-27
CN114555626B (zh) 2025-04-08
JP2022542291A (ja) 2022-09-30
WO2021019245A1 (en) 2021-02-04
US20220257784A1 (en) 2022-08-18
US12570695B2 (en) 2026-03-10
JP7682852B2 (ja) 2025-05-26
MX2022001288A (es) 2022-02-22
WO2021019243A1 (en) 2021-02-04
AU2020323739B2 (en) 2025-11-06
JP7620002B2 (ja) 2025-01-22
JP2025122030A (ja) 2025-08-20
MX2022001273A (es) 2022-02-22
BR112022001520A2 (pt) 2022-06-21
AU2020323739A1 (en) 2022-03-17
CN114341190A (zh) 2022-04-12
SA522431586B1 (ar) 2024-04-24
EP4003529A1 (en) 2022-06-01
AU2020322193B2 (en) 2026-02-19
WO2021019244A1 (en) 2021-02-04
KR20220049529A (ko) 2022-04-21
WO2021019246A1 (en) 2021-02-04
PH12022550173A1 (en) 2022-11-14
CN114555626A (zh) 2022-05-27
CA3148039A1 (en) 2021-02-04
TW202110485A (zh) 2021-03-16
US11970553B2 (en) 2024-04-30
US20220242911A1 (en) 2022-08-04
BR112022001532A2 (pt) 2022-06-07
CN114521197B (zh) 2025-04-11
IL290089A (en) 2022-03-01
CN114502598A (zh) 2022-05-13
AU2020319704A1 (en) 2022-03-17
EP4003530A1 (en) 2022-06-01
JP7704732B2 (ja) 2025-07-08
MX2022001290A (es) 2022-02-22
EP4003527A1 (en) 2022-06-01
US12606594B2 (en) 2026-04-21
CA3147570A1 (en) 2021-02-04
TW202118770A (zh) 2021-05-16
JP7579840B2 (ja) 2024-11-08
KR20220051345A (ko) 2022-04-26
JP2022542386A (ja) 2022-10-03
US20220227811A1 (en) 2022-07-21
AU2020319704B2 (en) 2025-08-14
JP2022544058A (ja) 2022-10-17
IL290093A (en) 2022-03-01
US12435107B2 (en) 2025-10-07

Similar Documents

Publication Publication Date Title
AU2020319704B2 (en) Heterotandem bicyclic peptide complex
US12049520B2 (en) Bicyclic peptide ligands specific for CD137
JP7551500B2 (ja) ヘテロタンデム二環式ペプチド複合体
EP4274838B1 (en) Bicyclic peptide ligands specific for nk cells
EP3755725A1 (en) Multimeric bicyclic peptide ligands
EP3894008A1 (en) Bicyclic peptide ligands specific for psma
US12630588B2 (en) Bicyclic peptide ligands specific for CD137
EA046294B1 (ru) Гетеротандемный бициклический пептидный комплекс
EA046193B1 (ru) Гетеротандемный бициклический пептидный комплекс

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240719

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241104

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241115

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241115

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250708

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250708

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260402

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260409

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260409

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260409